BIO18: Oncology surplus could drive down values

BIO18: Oncology surplus could drive down values

Source: 
Biopharma Dive
snippet: 

2018 is shaping up to be the second strongest dealmaking year in the last decade based on M&A activity during the first quarter, reports Syneos Health in its Dealmakers' Intentions Survey. Total deal values could reach between $200 billion to $250 billion this year, second to 2015's mark of $425 billion.